Biogen ALS Drug Granted FDA Priority Review, Triggering Aduhelm Déjà Vu
FDA accepted the NDA for tofersen based on a surrogate biomarker after a Phase III trial failure, echoing some elements of the Aduhelm experience, though in this instance the target patient population is ultra-niche.
